Compounds > sm 7368
Page last updated: 2024-11-12

sm 7368

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

SM 7368: inhibits expression of TNFalpha-induced MMP-9 expression; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11537217
SCHEMBL ID159312
MeSH IDM0491469

Synonyms (18)

Synonym
sm-7368
nf-kappab activation inhibitor iii
3-chloro-4-nitro-n-(5-nitro-2-thiazolyl)-benzamide
380623-76-7
AKOS021094457
SCHEMBL159312
DTXSID80468240
sm-7368, >=98% (hplc)
3-chloro-4-nitro-n-(5-nitro-1,3-thiazol-2-yl)benzamide
nf kappa b activation inhibitor iii
sm 7368
MS-24931
nf-b activation inhibitor iii
HY-116626
3-chloro-4-nitro-n-(5-nitrothiazol-2-yl)benzamide
CS-0066101
nf-(c)ab activation inhibitor iii
F75078
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's4 (66.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.97

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.97 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.97)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
quinoxalines
quinoxaline : A naphthyridine in which the nitrogens are at positions 1 and 4.		2.0610mancude organic heterobicyclic parent;
naphthyridine;
ortho-fused heteroarene
thiazoles
[no description available]		3.31601,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
tanshinone
tanshinone: from root of Salvia miltiorrhiza Bunge; RN given refers to tanshinone I; cardioprotective agent and neuroprotective agent		2.1310abietane diterpenoidanticoronaviral agent
carboxyaminoimidazole ribotide
carboxyaminoimidazole ribotide: reacts with alanosine to form antimetabolite; substrate for EC 4.1.1.21; structure in second source		2.06101-(phosphoribosyl)imidazole;
aminoimidazole;
imidazole-4-carboxylic acid		Escherichia coli metabolite;
mouse metabolite
n(2)-(gamma-d-glutamyl)-meso-2,2'-diaminopimelic acid
N(2)-(gamma-D-glutamyl)-meso-2,2'-diaminopimelic acid: intermediate in synthesis of FK-156 which is an immunostimulant; structure given in first source; RN given refers to (D)-isomer		2.0510
diaminopimelic acid
Diaminopimelic Acid: A diamino derivative of heptanedioic acid with amino groups at C-2 and C-6 and the general formula (COOH)CH(NH2)CH2CH2CH2CH(NH2)(COOH).. LL-2,6-diaminopimelic acid : A 2,6-diaminopimelic acid in which both chiral centres have S configuration. It is a component of bacterial cell wall.		2.05102,6-diaminopimelic acid;
amino acid zwitterion		Escherichia coli metabolite
bms345541
4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline: structure in first source		2.0610quinoxaline derivative
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.5120
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.5120
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		02.0510
Cardiac Remodeling, Ventricular
[description not available]		02.0810
Cardiac Failure
[description not available]		02.0810
Heart Failure
A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.		02.0810
Fibrosarcoma
A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)		02.0210